entertainment -WSS

entertainment

author：knowledge 2025-09-29 10:40:30 - browse：27

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Gene editing the human germline: What are the risks?

WSS

Biden White House, tech companies launch new safeguards around emerging AI technology

Prosecutors say FTX founder Sam Bankman

How Brent Saunders' Allergan experiment failed

How Brent Saunders' Allergan experiment failed

Why the advice to take all your antibiotics may be wrong

EMA weighs against approval for Mirati's lung cancer drug

hotspot

entertainment

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Gene editing the human germline: What are the risks?

Heart attack and stroke risk calculators need revising

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Trump demands the U.S. pay no more for drugs than other countries … again

How Brent Saunders' Allergan experiment failed

Novavax promises a turnaround & Lilly roils the obesity market

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

DIEP, the 'gold standard' of breast reconstruction, is under threat

Physicians and social media: If you see something, say something?

hotspot

Health AI adoption puts security, privacy startups on investors' radar

It's time to take a new tack for treating Alzheimer's

'The View' co

Why the advice to take all your antibiotics may be wrong

Physicians and social media: If you see something, say something?

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

focus

Wikipedia

focus

entertainment